The firm plans to use the cash to support commercial expansion of its NIPT to all US states and fund R&D for future diagnostic tests, including liquid biopsies.
The company is developing an RNA sequencing kit based on a technology that enables barcoding in a test tube format to prepare samples for single-cell profiling.
The company is developing a platform that is designed to provide an overview of an individual's health based on sequenced genetic data and other metrics.
The University of Utah spinout said it will use the funding to enhance and expand its NGS-based Explify microbe identification platform and support its lab.
The FDA and CDC call for a pause in administering Johnson & Johnson's SARS-CoV-2 vaccine while reports of rare blood clots are looked into, reports the Wall Street Journal.